Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PDE5A | O76074 | 11/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.50 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.50 |
| ▸ | PDE1A | P54750 | 2/20 | 0.50 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.50 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.50 |
| ▸ | PDE2A | O00408 | 1/20 | 0.50 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.50 |
| ▸ | PDE6D | O43924 | 1/20 | 0.50 |
| ▸ | PDE8A | O60658 | 1/20 | 0.50 |
| ▸ | PDE9A | O76083 | 1/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6207835 | 0.93 | TERT (0.65) | TERTKMT2AMEN1CA12CA9 | |
| SCHEMBL6207634 | 0.88 | TERT (0.53) | TERTKMT2ACYP3A4 | |
| SCHEMBL4563385 | 0.88 | TERT (0.53) | TERTKMT2AMEN1CA12CA9 | |
| SCHEMBL6332500 | 0.88 | KMT2A (0.52) | TERTKMT2AMEN1CA12CA9 | |
| SCHEMBL6492024 | 0.88 | TERT (0.53) | TERTKMT2AMEN1CA12CA9 | |
| SCHEMBL29897708 | 0.88 | TERT (0.53) | TERTKMT2AMEN1CA12CA9 | |
| SCHEMBL6492020 | 0.88 | TERT (0.53) | TERTKMT2AMEN1CA12CA9 | |
| SCHEMBL8125815 | 0.87 | TERT (0.62) | TERTKMT2APDE5APDE3BPDE3A | |
| SCHEMBL7253729 | 0.84 | TERT (0.58) | TERTKMT2APDE5APDE1APDE2A | |
| SCHEMBL15423767 | 0.84 | TERT (0.58) | TERTPDE5AHDAC1HDAC6HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221825-B2 | Pyrazolopyrimidinone compound and imidazo triazone compound for treating erectile dysfunction | ZHEJIANG DADE PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-12-29 | — | — | US | disclosed |
| US-20140018351-A1 | Pyrazolopyrimidinone Compound and Imidazo Triazone Compound for Treating Erectile Dysfunction | Zhejiang Date Pharmaceutical Group Co. Ltd (CN) | 2014-01-16 | — | — | US | disclosed |
| US-8071765-B2 | Process for the preparation of sildenafil and intermediates thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2011-12-06 | — | — | US | disclosed |
| EP-2168967-A1 | INTERMEDIATES FOR PREPARATION OF AN INHIBITOR OF PHOSPHODIESTERASE TYPE 5 | Galenicum Health, S.l. (ES) | 2010-03-31 | — | — | EP | disclosed |
| US-20100048897-A1 | PROCESS FOR THE PREPARATION OF SILDENAFIL AND INTERMEDIATES THEREOF | TOPHARMAN SHANGHAN CO., LTD. (CN) | 2010-02-25 | — | — | US | disclosed |
| US-20090062298-A1 | DEUTERIUM-ENRICHED SILDENAFIL | PROTIA, LLC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062298-A1 | DEUTERIUM-ENRICHED SILDENAFIL | PROTIA, LLC (US) | 2009-03-05 | — | — | US | disclosed |
| EP-2024369-A2 | NOVEL PROCESS FOR THE PREPARATION OF SILDENAFIL CITRATE | Matrix Laboratories Ltd (IN) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008152177-A1 | INTERMEDIATES FOR PREPARATION OF AN INHIBITOR OF PHOSPHODIESTERASE TYPE 5 | GALENICUM HEALTH, S.L. (ES) | 2008-12-18 | — | — | WO | disclosed |
| WO-2007141805-A2 | NOVEL PROCESS FOR THE PREPARATION OF SILDENAFIL CITRATE | MATRIX LABORATORIES LIMITED (IN) | 2007-12-13 | — | — | WO | disclosed |
| EP-0916675-B1 | Process for preparing sildenafil | PFIZER LTD (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2001022918-A2 | METHOD OF PREPARATION OF SILDENAFIL | INST FARMACEUTYCZNY (PL) | 2001-04-05 | — | — | WO | disclosed |
| EP-1077214-A1 | An improved process for preparing a pyrazolopyrimidinone derivative | Orchid Chemicals & Pharmaceuticals Ltd. (IN) | 2001-02-21 | — | — | EP | disclosed |
| EP-1002798-A1 | An improved process for preparing a therapeutically active pyrazolopyrimidinone derivative | Orchid Chemicals & Pharmaceuticals Ltd. (IN) | 2000-05-24 | — | — | EP | disclosed |
| US-6066735-A | TREATMENT OF ERECTILE DYSFUNCTION | PFIZER INC. (US) | 2000-05-23 | — | — | US | disclosed |
| US-5955611-A | CYCLIZATION OF DIAMIDEPYRAZOLE TO FORM PYRIMIDONE OF PYRAZOLE | PFIZER INC. (US) | 1999-09-21 | — | — | US | disclosed |
| EP-0812845-B1 | Process for preparing sildenafil | PFIZER LTD (GB) | 1999-07-14 | — | — | EP | disclosed |
| EP-0916675-A2 | Process for preparing sildenafil | Pfizer Limited (GB) | 1999-05-19 | — | — | EP | disclosed |
| EP-0812845-A1 | Process for preparing sildenafil | Pfizer Limited (GB) | 1997-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018351-A1 | Pyrazolopyrimidinone Compound and Imidazo Triazone Compound for Treating Erectile Dysfunction | PDE3A, PDE3B, PDE5A | TERT 1504/4885KMT2A 2838/4885MEN1 3388/4885 |
| US-20100048897-A1 | PROCESS FOR THE PREPARATION OF SILDENAFIL AND INTERMEDIATES THEREOF | PDE5A, NOX5, PDE3A | TERT 3926/4885KMT2A 3562/4885MEN1 2948/4885 |
| US-20090062298-A1 | DEUTERIUM-ENRICHED SILDENAFIL | PDE5A, PDE3A, PDE2A | TERT 3780/4885KMT2A 1556/4885MEN1 2318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.